Actively Recruiting
Liquid Biospy for Urinary Cancers
Led by IRCCS San Raffaele · Updated on 2023-11-07
450
Participants Needed
1
Research Sites
417 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The project aims to characterize the prognostic role of CTCs in Bladder cancer patients, with the specific aims to better stratify patients with non-muscle invasive bladder cancer at the first transurethral resection of tumor and to identify urothelial biomarker expressed by CTCs.
CONDITIONS
Official Title
Liquid Biospy for Urinary Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of urothelial neoplasia, naive for therapy
You will not qualify if you...
- Absence of previous neoplastic disease or genetic diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Urology Department
Milan, Italy, 20132
Actively Recruiting
Research Team
M
Massimo Alfano, PhD
CONTACT
C
Chiara Venegoni, Dr.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here